Biondvax Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.08.18	BiondVax Moves to New Universal Flu Vaccine Manufacturing Facility (PR Newswire)
14.08.18	BiondVax Receives Second €6M Tranche Disbursement From the European Investment Bank (EIB) (PR Newswire)
21.05.18	Vanguard Announces Plans To Launch Total World Bond ETF (PR Newswire)
30.04.18	BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update (PR Newswire)
11.04.18	BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United States (PR Newswire)
18.09.17	BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment Option (PR Newswire)
13.09.17	BiondVax Announces Public Offering of American Depositary Shares (PR Newswire)
31.08.17	Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange (PR Newswire)
14.08.17	BiondVax Receives Additional Grant Funding (PR Newswire)
20.07.17	BiondVax Reports Positive Phase 2b Clinical Trial Results for its Universal Flu Vaccine (PR Newswire)
18.07.17	BiondVax Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine (PR Newswire)
28.06.17	BiondVax's CEO Provides First Half 2017 General Corporate Update (PR Newswire)
19.06.17	European Investment Bank (EIB) Supports Late-Stage Development and Production of BiondVax's Universal Flu Vaccine Candidate Under Horizon 2020 Initiative (PR Newswire)
30.03.17	BiondVax Approved for Grant from Israel's Ministry of Economy and Industry to Build Facility for Commercial Scale Production of its Universal Flu Vaccine (PR Newswire)
13.03.17	BiondVax Publishes Regulatory Approval Strategy for Novel Universal Flu Vaccines in Future Virology Journal (PR Newswire)
24.02.17	Vanguard Reports Third Round Of Expense Ratio Reductions Resulting In $143 Million In Cumulative Savings For Investors (PR Newswire)
12.01.17	Back to the Future: Study Published in Vaccine Journal Indicates BiondVax's Universal Flu Vaccine Candidate May Cover Strains Which Don't yet Exist (PR Newswire)
02.01.17	BiondVax Receives $US 2.8 Million Investment From Angels High Tech Investments Ltd. (PR Newswire)
29.11.16	BiondVax Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine Candidate is Safe and Well Tolerated (PR Newswire)
22.11.16	Highly Pathogenic Bird Flu Spreading Across Europe and Asia; BiondVax’s Universal Flu Vaccine Candidate Also Covers these Potential Pandemic Strains (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	79.88	2.70 %	K V
Roche Hldg G	264.40	2.68 %	K V
Lonza Grp	554.20	2.29 %	K V
Swiss Re	134.85	1.70 %	K V
Novartis	90.39	1.61 %	K V
ABB	49.48	-0.26 %	K V
Geberit	513.60	-0.35 %	K V
Sika	216.90	-0.37 %	K V
Kuehne+Nagel Int	208.50	-0.43 %	K V
Holcim	88.08	-0.45 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Biondvax Pharmaceuticals Ltd.

Aktien Top/Flop

Meistgelesene Nachrichten